Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Amarin Corp Plc

AMRN

Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.

Last trade $11.25
Day change -$0.06 (-0.53%)
Day range $11.22 – $11.32
Volume 37,524
Market cap $475M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$475.5M
Price / earnings
—
Price / book
1.07×
Price / sales
2.7×
EV / sales
1.81×
EV / EBITDA
-14.51×

Profitability

Earnings per share
-$0.46
Return on assets
-3.02%
Return on equity
-4.31%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.5×
Quick ratio
2.59×
Cash ratio
0.89×

Cash flow

Price / cash flow
12.68×
Price / free cash flow
12.68×
Free cash flow
$37.49M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AMRN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$39.55M$42.21M$45.13M$49.22M$49.67M$72.74M$42.02M$62.31M
Cost of revenue$23.37M$27.22M$27.36M$26.05M$27.46M$22.38M$16.89M$71.87M
Gross profit$16.18M$14.99M$17.77M$23.17M$22.21M$50.36M$25.13M-$9.57M
Selling, general and administrative$14.34M$22.19M$21.12M$20.06M$19.7M$38.67M$36.57M$36.97M
Research and development$4.21M$4.77M$4.67M$5.37M$4.21M$4.92M$5.31M$5.99M
Total operating expenses$18.54M$27M$29.1M$29.49M$33.31M$66.35M$41.89M$42.96M
Operating income-$2.36M-$12.01M-$11.33M-$6.33M-$11.1M-$15.99M-$16.76M-$52.52M
Interest expense$0$0$0-$7K$0$0$0-$7K
Income before taxes$315K-$7.87M-$8.72M-$852K-$8.12M-$13.45M-$13.63M-$49.91M
Income taxes$70K-$219K$1.79M$372K-$377K$689K$2.07M-$1.29M
Net income$245K-$7.65M-$10.51M-$1.22M-$7.74M-$14.14M-$15.7M-$48.62M
Net income attributable to common shareholders$245K-$7.65M-$10.51M-$1.22M-$7.74M-$14.14M-$15.7M-$48.62M
EBITDA-$1.72M-$11.33M-$7.37M-$1.56M-$830K$7.5M-$16.03M-$51.79M
Basic earnings per share$0.00-$0.02-$0.03$0.00-$0.02-$0.03-$0.04-$0.12
Diluted earnings per share$0.00-$0.02-$0.03$0.00-$0.02-$0.03-$0.04-$0.12

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark

Amarin Corporation reported Q3 2026 adjusted earnings of 8 cents per ADS, beating estimates despite a 57.9% year-over-year decline. Total revenues of $39.6 million missed consensus estimates of $45 million, declining 20.4% YoY primarily due to a 30% drop in U.S. Vascepa sales amid generic competition and pricing pressure. However, global in-market demand for Vascepa/Vazkepa increased 55% YoY. The company maintained a strong balance sheet with $323.4 million in cash and investments while remaining debt-free.

Zacks Investment Research

FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer

ImmunityBio received FDA approval to expand Anktiva's label for treating BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only disease. The approval, granted three months ahead of schedule, now covers all BCG-unresponsive NMIBC patients. Anktiva sales surged 121% year-over-year to $95 million in the first half of 2026, driven by strong physician adoption and new prescriber demand.

Zacks Investment Research

Here's Why You Should Add EYPT Stock to Your Portfolio Now

EyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating.

Zacks Investment Research

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals.

Zacks Investment Research

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 11, 20251-for-20reverse split
Jan 18, 20081-for-10reverse split